Celia Eckert Sells 3,244 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the transaction, the senior vice president directly owned 78,685 shares in the company, valued at approximately $885,206.25. The trade was a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Celia Eckert also recently made the following trade(s):

• On Friday, March 6th, Celia Eckert sold 1,767 shares of Xencor stock. The shares were sold at an average price of $11.02, for a total transaction of $19,472.34.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The stock was sold at an average price of $11.90, for a total transaction of $17,754.80.

Xencor Trading Up 0.9%

Shares of Xencor stock opened at $11.98 on Wednesday. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69. The company’s fifty day simple moving average is $12.67 and its 200-day simple moving average is $13.06. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. The stock has a market capitalization of $878.61 million, a PE ratio of -9.66 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same period in the prior year, the business posted ($0.62) EPS. Xencor’s revenue was down 46.6% on a year-over-year basis. As a group, equities analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Barclays boosted their price objective on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Truist Financial assumed coverage on shares of Xencor in a research report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. lifted its holdings in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares during the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Xencor in the third quarter worth $44,000. Federated Hermes Inc. lifted its holdings in shares of Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Xencor by 85.5% during the third quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 2,424 shares during the last quarter.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an earnings beat on Feb. 25 (EPS -$0.09 vs. consensus -$0.64), which can support sentiment despite revenue weakness; investors often reward upside to EPS expectations. Earnings Summary
• Positive Sentiment: Analyst coverage includes new/raised targets (Truist coverage with a Buy, Barclays raising its target to $27), which provides external validation and upside to the consensus price target (~$25). Analyst Notes
• Neutral Sentiment: Institutional holders show modest position changes (small increases by several funds); these are routine rebalances and not a clear directional signal. Institutional Activity
• Negative Sentiment: Xencor and Genentech agreed to end their protein-therapeutics collaboration — this removes a strategic partner that could have provided development resources, milestones or royalties; termination may return rights to Xencor but creates near-term uncertainty for the affected programs and potential revenue. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Clustered insider selling by senior executives was disclosed this week: CEO Bassil Dahiyat sold ~21,476 shares across Mar 5–6, SVP Celia Eckert sold ~5,011 shares, and VP John Desjarlais sold ~6,620 shares (transactions at ~$11–$11.90 per share). While each sale reduces insider holdings only a few percent, the timing and concentration can be read negatively absent a disclosed 10b5‑1 plan. Relevant filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.